
IMA - Industria Macchine Automatiche S.p.A.
IMA
With €2.5 billion in annual sales and 55 manufacturing plants spanning four continents, IMA Group has quietly assembled one of the deepest fortresses in pharmaceutical packaging machinery. Founded in 1961 in Bologna's Packaging Valley, the company grew through dozens of strategic acquisitions into the world's dominant supplier of blister packing, cartoning and capsule-filling lines for pharma, medical devices and cosmetics. Its C80/C90 blister machines and Adapta capsule fillers are installed in virtually every major drugmaker's plant, and the group's EBITDA has surged more than 70% over the past three years.
Strengths:
• Oligopolistic position in pharma packaging: IMA is one of only two full-line suppliers of blister packaging and cartoning systems trusted by the world's top 20 pharmaceutical companies.
• Unmatched global footprint: 55 plants in Italy, Germany, the USA, India and China plus a symbiosis of nearly 30 specialist machine shops in Bologna give it vertical integration rivals cannot copy.
• Cross-industry diversification: the new IMA MED-TECH unit assembles automated lines for single-use medical devices, insulating revenue from pharma capex cycles.
• AI-driven quality: heavy R&D investment in machine-vision inspection is converting into proprietary in-line defect-detection systems.
• Private-equity backing: BC Partners' patient capital funds long-horizon R&D without quarterly earnings pressure.
Weaknesses:
• High leverage from serial M&A: S&P flags a €830 million bond maturing January 2028; refinancing risk weighs on free cash flow.
• Integration complexity: absorbing more than 30 acquired brands creates software and manufacturing fragmentation.
• European concentration: a majority of engineering headcount remains in Italy, exposing cost base to EU labor inflation.Read MoreShow Less
Strengths:
• Oligopolistic position in pharma packaging: IMA is one of only two full-line suppliers of blister packaging and cartoning systems trusted by the world's top 20 pharmaceutical companies.
• Unmatched global footprint: 55 plants in Italy, Germany, the USA, India and China plus a symbiosis of nearly 30 specialist machine shops in Bologna give it vertical integration rivals cannot copy.
• Cross-industry diversification: the new IMA MED-TECH unit assembles automated lines for single-use medical devices, insulating revenue from pharma capex cycles.
• AI-driven quality: heavy R&D investment in machine-vision inspection is converting into proprietary in-line defect-detection systems.
• Private-equity backing: BC Partners' patient capital funds long-horizon R&D without quarterly earnings pressure.
Weaknesses:
• High leverage from serial M&A: S&P flags a €830 million bond maturing January 2028; refinancing risk weighs on free cash flow.
• Integration complexity: absorbing more than 30 acquired brands creates software and manufacturing fragmentation.
• European concentration: a majority of engineering headcount remains in Italy, exposing cost base to EU labor inflation.
• Blister packing lines C80/C90 for tablets, capsules and vials with integrated vision inspection
• Capsule filling machines Adapta series for powder, pellet and liquid formulations
• Cartoning and end-of-line packaging systems for pharma and nutraceuticals
• Aseptic and cleanroom processing equipment for injectables
Medical Device Automation – Core Business
• Automated assembly lines for single-use medical devices IMA MED-TECH
• Clinical and research facility automation
Cosmetics & Food Packaging – Core Business
• Tube filling, cartoning and bundling lines for cosmetics and personal care
• Secondary packaging systems for food and confectionery
Industrial Robotics & Vision – Core Business
• Machine-vision inspection and AI-based defect detection
• Robotic palletizing and depalletizing systems
Quick Facts
Headquarters
Founded
Employees
Revenue
Factories
Presence
Categories
13 categories · scroll for more
Related
Similar listed companies
- Abbott Laboratories· $231 B
- Siemens AG· $222 B
- Danaher Corporation· $207 B
- John Deere· $179 B
- Schneider Electric SE· $154 B
- GE Vernova· $149 B
Data Sources & Methodology
This corporate profile is compiled from publicly available sources including company annual reports, SEC/regulatory filings, official press releases, and verified third-party industry databases. Financial figures reflect the most recent fiscal year disclosures and are cross-validated across multiple independent references.
VerityRank Score is calculated using a proprietary multi-dimensional model evaluating market presence, financial strength, operational scale, innovation capacity, and brand influence. Individual dimension scores are normalized against industry peers and updated quarterly.
Disclaimer: This profile is for informational purposes only. VerityRank makes no warranties regarding completeness or timeliness. This content does not constitute investment advice or endorsement.
Key references: Official Website , Data Sources:
• IMA (company) - Wikipedia
• About IMA Group | Corporate Overview
• IMA Group | Invest Europe Success Story
• S&P Global Ratings - IMA Outlook
• IMA MED-TECH Official Page
